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Abstract
The expression of GnRH (GnRH-I, LHRH) and its receptor as a part of an autocrine regulatory
system of cell proliferation has been demonstrated in a number of human malignant tumors,
including cancers of the ovary. The proliferation of human ovarian cancer cell lines is time- and
dose-dependently reduced by GnRH and its superagonistic analogs. The classical GnRH receptor
signal-transduction mechanisms, known to operate in the pituitary, are not involved in the
mediation of antiproliferative effects of GnRH analogs in these cancer cells. The GnRH receptor
rather interacts with the mitogenic signal transduction of growth-factor receptors and related
oncogene products associated with tyrosine kinase activity via activation of a phosphotyrosine
phosphatase resulting in downregulation of cancer cell proliferation. In addition GnRH activates
nucleus factor κB (NFκB) and protects the cancer cells from apoptosis. Furthermore GnRH
induces activation of the c-Jun N-terminal kinase/activator protein-1 (JNK/AP-1) pathway
independent of the known AP-1 activators, protein kinase (PKC) or mitogen activated protein
kinase (MAPK/ERK).
Recently it was shown that human ovarian cancer cells express a putative second GnRH receptor
specific for GnRH type II (GnRH-II). The proliferation of these cells is dose- and time-dependently
reduced by GnRH-II in a greater extent than by GnRH-I (GnRH, LHRH) superagonists. In previous
studies we have demonstrated that in ovarian cancer cell lines except for the EFO-27 cell line
GnRH-I antagonist Cetrorelix has comparable antiproliferative effects as GnRH-I agonists
indicating that the dichotomy of GnRH-I agonists and antagonists might not apply to the GnRH-I
system in cancer cells. After GnRH-I receptor knock down the antiproliferative effects of GnRH-I
agonist Triptorelin were abrogated while the effects of GnRH-I antagonist Cetrorelix and GnRH-
II were still existing. In addition, in the ovarian cancer cell line EFO-27 GnRH-I receptor but not
putative GnRH-II receptor expression was found. These data suggest that in ovarian cancer cells
the antiproliferative effects of GnRH-I antagonist Cetrorelix and GnRH-II are not mediated
through the GnRH-I receptor.
Introduction
The hypothalamic decapeptide gonadotropin releasing
hormone (GnRH, GnRH-I), also called luteinizing hor-
mone releasing hormone (LHRH), plays a key role in the
regulation of mammalian reproduction [1–3]. It is
released from the hypothalamus in a pulsatile manner
and stimulates the synthesis and release of luteinizing
hormone (LH) and follicle stimulating hormone (FSH).
In addition to this classic hypophysiotropic actions,
GnRH functions as a modulator of the activity of diverse
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systems in the brain and many peripheral organs [for
review see [4]]. An autocrine/paracrine function of GnRH
has been suggested to exist, for instance, in the placenta,
granulosa cells, myometrium, and lymphoid cells [for
review see [4,5]]. In addition, it is probable that such
GnRH-I-based autocrine systems are present in a number
of human malignant tumors including cancers of the
ovary, endometrium, breast and prostate [for review see
[4,5]].
The GnRH-I system in human ovarian cancers
In earlier studies the expression of GnRH-I and its receptor
(GnRH-I receptor) as well as direct antiproliferative effects
of GnRH-I and its analogs have been demonstrated in a
number of malignant human tumors, including cancers of
the ovary [6–14]. Data available today suggest that
approximately 80% of ovarian cancers express high-affin-
ity GnRH-I receptors [4,5,15]. These findings suggested
the presence of a local regulatory system based on GnRH-
I. The same situation was found in endometrial, breast
and prostate cancer cells [4,5,15,16].
The in vitro proliferation of a variety of human tumor cell
lines, including those from ovarian cancers can be inhib-
ited by GnRH-I and its agonistic analogs in a dose- and
time-dependent manner [4,9,11,12,17–20]. In most
human ovarian cancer cells except for the ovarian cancer
cell line EFO-27 GnRH-I antagonists act like agonists indi-
cating that the dichotomy of GnRH-I agonists and antag-
onists does not exist in tumor cells [5,9]. Using human
ovarian cancer cell line OV-1063 xenografted into nude
mice, Yano et al. [12] demonstrated a significant inhibi-
tion of tumor growth by chronic treatment with the
GnRH-I antagonist Cetrorelix but not with the GnRH-I
agonist Triptorelin. As both GnRH-I analogs induced a
comparable suppression of the pituitary-gonadal axis, the
authors speculated that in vivo anti tumor effects of
Cetrorelix were exerted directly on GnRH-I receptors in
tumors [8]. The findings on direct anti tumor effects of
GnRH-I analogs in ovarian and endometrial cancer
reported by several other groups are completely or partly
in agreement with the results described earlier [4,8,21,22].
In contrast, other investigators failed to detect direct anti
tumor effects of GnRH-I analogs in human ovarian and
endometrial cancer cell lines or observed them only at
extremely high GnRH-I analog concentrations [23–25].
These discrepancies might be due to the fact that probably
the majority of the cell lines used by these authors did not
express high-affinity GnRH-I receptors [4,26]. Alterna-
tively, differences in culture or experimental conditions as
well as in the types of GnRH-I analogs used might be
responsible for the observed variance. In the case of pros-
tate cancer, several groups reported direct antiproliferative
effects of GnRH-I analogs in vitro and in animal in vivo
models, which could be mediated through specific GnRH-
I-binding sites [1,27–32].
The proliferation of human ovarian cancer cells was sig-
nificantly increased after treatment with an antiserum to
GnRH-I, suggesting that GnRH-I produced by human
ovarian cancer cells acts as a negative autocrine regulator
of proliferation [33]. In contrast, Arencibia and Schally
[34] have recently reported that in ES-2 human ovarian
cancer cells GnRH-I agonist Triptorelin at 10 ng/ml stim-
ulated the proliferation in vitro after 48 h, but was inhib-
itory after 72 h and at concentrations of 1000 ng/ml.
GnRH-I antagonist Cetrorelix inhibited growth of ES-2
cell line only at 1000 ng/ml. The incubation of ES-2 ovar-
ian cancer cells in vitro with an GnRH-I antibody inhib-
ited cell proliferation in a time and concentration-
dependent manner. These results suggest that GnRH-I
may function as an autocrine growth factor in this ovarian
cancer cell line [34]. Differences between tumor cell lines
e.g. variances in G-protein coupling and signaling might
explain these discrepancies.
Signaling mechanisms mediating the direct anti-
tumor effects of GnRH-I
During the last ten years, the signaling mechanisms medi-
ating the antiproliferative effects of GnRH-I analogs in
ovarian, endometrial and breast cancer cells have been
elucidated. The signaling mechanism of GnRH-I receptor
in human cancers is quite different from that in pituitary
gonadotrophs, where GnRH-I receptors couple to G-pro-
tein  αq and activate phospholipase C (PLC), protein
kinase C (PKC), and adenylyl cyclase (AC) [reviewed in
[4]]. Although we could clearly demonstrate the activa-
tion of PLC, PKC, and AC in these tumor cells by pharma-
cological stimuli [35], the signaling pathways induced by
GnRH-I in pituitary gonadotrophs were not activated by
GnRH-I agonist Triptorelin in ovarian, endometrial and
breast cancer cell lines [35,36]. We found, however, that
after binding of its ligand, the GnRH-I receptor in these
cancers couples to G-protein αi and activates a phospho-
tyrosine phosphatase (PTP) [35–40] (Fig. 1A). This PTP
dephosphorylates EGF receptors [36]. As a result,
mitogenic signaling induced by EGF binding to its recep-
tor is abrogated leading to a suppression of EGF-induced
activation of mitogen-activated protein kinase (MAPK)
[35], c-fos expression [41], and EGF-induced proliferation
[35] (Fig. 1A). These findings are in accord with reports
that GnRH-I analogs reduce expression of growth factor
receptors and their mRNA [12,42,43] (Fig. 1B) and/or
growth factor induced tyrosine kinase activity [35,37–
39,42,44–46]. The reason for the differences of the GnRH-
I receptor signaling between pituitary gonadotrophs and
tumor cells remains unclear, as we could not find muta-
tions or splice variants in the tumor GnRH-I receptor
which might explain this phenomenon.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/65
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Recently, it was speculated that induction of apoptosis
might be involved in the antiproliferative activity of
GnRH-I and its analogs [47–49]. However, though we
have tried to show induction of apoptosis by GnRH-I ana-
logs, we have found it only in one (Ca-Ov-3) of nine
(EFO-21, EFO-27, OVCAR-3, AN-3-CA, Ca-Ov-3, SK-OV-
3) ovarian cancer cell lines [[50] and unpublished results].
In contrast, we found that GnRH-I agonist Triptorelin
reduced apoptosis induced by the cytotoxic agent doxoru-
bicin. Since Triptorelin-induced reduction of Doxoru-
bicin-induced apoptosis was blocked by inhibition of
nucleus factor kappa B (NFκB) translocation into the
nucleus and Triptorelin was shown to induce NFκB activa-
tion (Fig. 1C), we concluded that GnRH-I has an antiap-
GnRH-I and GnRH-II signaling in human gynecological cancer cells Figure 1
GnRH-I and GnRH-II signaling in human gynecological cancer cells: A) GnRH-I activates a phosphotyrosine phosphatase (PTP) 
inhibiting the mitogenic signal transduction of growth factor receptors resulting in downregulation of cell proliferation. B) 
GnRH-I downregulates epidermal growth factor (EGF) receptor mRNA expression. C) Activated GnRH-I receptor induces 
nucleus factor κB (NFκB) activation and nuclear translocation of activated NFκB. Activated NFκB now couples to κB DNA 
binding sites and induces expression of anti-apoptotic mechanisms. D) GnRH-I activates c-Jun N-terminal kinase (JNK), induces 
JunD-DNA binding and stimulates activator protein (AP-1) activity, resulting in reduced proliferation as indicated by increased 
G0/1 phase of cell cycle and decreased DNA synthesis. E) Unknown signal transduction of a putative human GnRH-II receptor. 
In human gynecological cancer cells GnRH-I analogs mediate antiproliferative actions via inhibition of growth factor-induced 
mitogenic signal transduction. In addition GnRH-I induces growth factor receptor downregulation. GnRH-I protects the cancer 
cells from apoptosis via activation of NFκB, stimulates AP-1 activity and extends cell cycle. PPTK, receptor protein tyrosine 
kinase; GRB2, adaptor protein; SOS, guanine nucleotide exchange factor; RAS, small GTPase; RAF, a protein-serine/threonine 
kinase; MAPK-K, mitogen activated kinase kinase; MAPK, mitogen activated kinase; TCF, transcription factor; IκB, inhibitory 
κB; Gq, G-protein αq; Gi, G-protein αi; p50, p65, NFκB subunits.
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optotic effect mediated through NFκB activation in these
human ovarian cancer cells [50]. This possibility to
protect ovarian cancer cells from programmed cell death
is a new and important feature in GnRH-I signaling in
ovarian tumors apart from the inhibitory interference
with the mitogenic pathway.
Recently, it became evident that it is not only mitogenic
signaling of growth factor receptors that is modulated by
GnRH-I in human cancers. In human ovarian and
endometrial cancer cells GnRH-I agonist Triptorelin stim-
ulates the activity of activator protein-1 (AP-1) mediated
through pertussis toxin-sensitive G-protein αi (Fig. 1D).
In addition, Triptorelin activates JNK, known to activate
AP-1 [51] (Fig. 1D). In earlier investigations we have
shown that Triptorelin does not activate phospholipase C
(PLC) and protein kinase C (PKC) in endometrial and
ovarian cancer cells [35]. In addition, it has been demon-
strated that Triptorelin inhibits growth factor-induced
mitogen activated protein kinase (MAPK, ERK) activity
[35]. Thus Triptorelin-induced activation of the JNK/AP-1
pathway in endometrial cancer cells is independent of the
known AP-1 activators, PKC or MAPK (ERK) (Fig. 1D).
In ovarian and endometrial cancer cells GnRH-I analogs
mediate antiproliferative actions via inhibition of growth
factor-induced mitogenic signal transduction. GnRH-I
agonist Triptorelin protects the cancer cells from apopto-
sis via activation of NFκB, and Triptorelin stimulates AP-1
and JNK activity. Recently Yamauchi et al. [52] found that
JNK is involved in inhibition of cell proliferation induced
by α1B-adrenergic receptor in human embryonic kidney
cells. In a study in rats, c-jun  mRNA depression and
endometrial epithelial cell proliferation were suggested to
be linked [53]. In UT-OC-3 ovarian cancer cells cytokines
have inhibitory effects on cell proliferation and activate
AP-1 and NFκB [54]. Since the antiproliferative GnRH-I
agonist Triptorelin activates the JNK/c-jun pathway and
JNK/c-jun was found to be involved in downregulation of
cell proliferation in different systems, it seems reasonable
to speculate that the JNK/c-jun pathway is involved in the
antiproliferative actions of the GnRH agonist Triptorelin.
In addition, we have shown that GnRH-I agonist Triptore-
lin induces JunD-DNA binding, resulting in reduced pro-
liferation as indicated by increased G0/1 phase of cell cycle
and decreased DNA synthesis (Fig. 1D). Since GnRH-I
activates NFκB and protects ovarian cancer cells from
Doxorubicin-induced apoptosis and JunD is shown to
decrease cell cycle and cell proliferation, we propose that
JunD activated by GnRH-I acts as a modulator of cell pro-
liferation and cooperates with the anti-apoptotic and anti-
mitogenic functions of GnRH-I [55].
GnRH-II and its receptor
In non-mammalian vertebrates it became evident that
three structural variants of GnRH were present in individ-
ual species [56,57]. A similar situation seems to exist in
mammals. One of these GnRH variants is GnRH-II, which
is totally conserved in structure in the evolution from fish
to mammals [58,59]. In human granulosa-luteal cells
expression of GnRH-II was found [60]. In these cells
GnRH-I agonists exerted a biphasic effect on GnRH-I
receptor density, while GnRH-II agonists induced a down-
regulation of GnRH-I receptor expression and of GnRH-II
itself [60]. Recently Millar et al. cloned a type II GnRH
receptor from the marmoset monkey which is highly
selective for GnRH-II [61]. At the same time Neill et al.
cloned the GnRH-II receptor from the rhesus monkey
[62]. Only 41% (marmoset GnRH-II receptor) and 39%
(rhesus monkey GnRH-II receptor) identities with the
GnRH-I receptor have been reported [61,62]. In contrast
to the GnRH-I receptor the GnRH-II receptor in the mar-
moset and rhesus monkey has a C-terminal, cytoplasmatic
tail resulting in a more rapid internalization [61,62].
Using RT-PCR and Southern blot analysis we could
recently show that human ovarian and endometrial can-
cer cells express a putative second GnRH receptor specific
for GnRH-II [63] (Fig. 1E). The proliferation of these cell
lines was reduced in a dose- and time-dependent manner
by native GnRH-II. These effects were significantly higher
than the antiproliferative effects of equimolar doses of
GnRH-I agonist Triptorelin [63]. In the GnRH-II receptor
mRNA positive but GnRH-I receptor negative ovarian can-
cer cell line SK-OV-3 native GnRH-II but not GnRH-I ago-
nist Triptorelin had antiproliferative effects [63]. In
previous studies we have demonstrated that in ovarian
cancer cell lines except for the EFO-27 cell line GnRH-I
antagonist Cetrorelix has comparable antiproliferative
effects as GnRH-I agonists indicating that the dichotomy
of GnRH-I agonists and antagonists might not apply to
the GnRH-I system in cancer cells [9] After GnRH-I recep-
tor knock down in EFO-21 and OVCAR-3 human ovarian
cancer cell lines the antiproliferative effects of GnRH-I
agonist Triptorelin were abrogated while the effects of
GnRH-I antagonist Cetrorelix and GnRH-II were still exist-
ing  [unpublished results]. In addition, in the ovarian
cancer cell line EFO-27 GnRH-I receptor but not putative
GnRH-II receptor expression was found [unpublished
results]. These data suggest that in ovarian and endome-
trial cancer cells the antiproliferative effects of GnRH-I
antagonist Cetrorelix and GnRH-II are not mediated
through the GnRH-I receptor. It is possible that these anti-
proliferative effects are mediated through a putative
GnRH-II receptor. However, the human GnRH-II receptor
is expressed as a variety of splice variants [64] and a func-
tional human GnRH-II receptor transcript has not been
found until now. Further investigations are required toReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/65
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determine whether these GnRH-II receptor splice variants
translate to functional proteins.
Gonadotropin biosynthesis and secretion by GnRH-I can
be mediated by activation of MAP kinases. Therefore, Mil-
lar et al. [61] assessed the capacity of both human GnRH-
I receptor and marmoset GnRH-II receptor to activate the
MAP kinases ERK2, JNK, and p38α in COS-7 cells trans-
fected with either the human GnRH-I receptor or the mar-
moset GnRH-II receptor. At the GnRH-I receptor, GnRH-I
was considerably more potent than GnRH-II in activating
ERK2 whereas at the GnRH-II receptor, GnRH-II was
markedly more potent than GnRH-I [61]. Neither GnRH-
I receptor nor GnRH-II receptor stimulation resulted in
activation of JNK [61]. Activation of p38α was detected on
stimulation of GnRH-II receptor with GnRH-II but not
with stimulation of GnRH-I receptor with GnRH-I [61].
These data suggest that there are distinct differences in the
signal transduction by the two GnRH receptors. However,
the signal transduction mechanisms mediating the anti-
proliferative activity of GnRH-II in human ovarian cancer
cells are not known (Fig. 1E).
As the antiproliferative activity of native GnRH-II is signif-
icantly superior to that of the GnRH-I superagonists,
superactive agonists of GnRH-II might become efficacious
drugs for the therapy of human cancers. However, the
more widely distributed expression pattern of GnRH-II
receptor [61] could limit the effectiveness of GnRH-II
agonists.
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